Respiratory Treatments Hit Hardest By HTA Terminations In England
• By Leela Barham
Availability of respiratory disease treatments are affected by failure to submit evidence to NICE health technology appraisals in England. (Shutterstock)
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
